Patients characteristics and tuberculin skin test (TST) conversion rate.
| Characteristics | All Participants (%), n = 86 | TST Conversion No. (%) | Multivariate OR (95% CI) |
|---|---|---|---|
| Age, yrs, mean (SD) | 39.3 (15.8) | ||
| ≤ 29 | 29 (33.7) | 7 (24) | 1.00 |
| 30–39 | 17 (19.8) | 10 (58.8)* | 3.93 (0.82–18.86) |
| 40–49 | 14 (16.3) | 7 (50) | 4.39 (0.68–28.27) |
| ≥ 50 | 26 (30.2) | 4 (15.4) | 0.78 (0.09–6.71) |
| Women, no. (%) | 48 (55.8) | 10 (20.8) | 0.35 (0.08–1.62) |
| Diagnosis | |||
| RA | 40 (46.5) | 7 (17.5) | 1.00 |
| AS | 34 (39.5) | 17 (50) | 1.01 (0.12–8.75) |
| JRA | 9 (10.5) | 1 (11.1) | 0.44 (0.02–9.67) |
| Other | 3 (3.5) | 3 (100) | — |
| Tuberculin skin tested in the past | 23 (26.7) | 7 (30.4) | |
| BCG vaccination | 77 (89.5) | 23 (29.9) | 0.34 (0.08–1.39) |
| Duration of TNF inhibitor therapy | |||
| 1–2 yrs | 35 (40.7) | 7 (20) | 1.00 |
| 2–3 yrs | 26 (30.2) | 10 (38.5) | 2.78 (0.68–11.38) |
| ≥ 3 yrs | 25 (29.1) | 11 (44)* | 3.44 (0.83–14.22) |
| TNF antagonists | |||
| Etanercept | 66 (76.7) | 20 (30.3) | 1.00 |
| Infliximab | 20 (23.3) | 8 (40) | 1.53 (0.54–4.33) |
| DMARD, no. (%) | 49 (57) | 13 (26.5) | 0.53 (0.21–1.32) |
| Corticosteroids, no. (%) | 35 (40.7) | 5 (14.3) | 0.35 (0.08–1.62) |
RA: rheumatoid arthritis; AS: ankylosing spondylitis; JRA: juvenile rheumatoid arthritis; BCG: bacillus Calmette-Guérin; TNF: tumor necrosis factor; DMARD: disease modifying antirheumatic drugs; OR: odds ratio; CI: confidence interval,
↵* p < 0.10.